Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000631
Chunk: 33

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 33
---
 of Timothy A. Springer, Ph.D.) |     |                      721,361 |     |     $14,427,220 |
| Chafen Lu, Ph.D.                                           |     |                        1,307 |     |         $26,140 |

2023 Private Placement In the 2023 Private Placement, we entered into a securities purchase agreement pursuant to which we issued and sold an aggregate of 149,330.115 shares of Series A Preferred Stock, each of which was converted or is convertible into 33.333 shares of Common Stock, for an aggregate purchase price of approximately $60.25 million. Timothy A. Springer, Ph.D., one of the Selling Stockholders and a member of our Board of Directors, participated in the 2023 Private Placement and was party to the 2023 RRA. TAS is affiliated with Dr. Springer and TAS also participated in the 2023 Private Placement and was party to the 2023 RRA. The following table sets forth the number of shares of Series A Preferred Stock purchased in 2023 Private Placement by such parties:

| Name                                                       |     | Shares of Series A Preferred 
              Stock Purchased |     | Total Aggregate 
  Purchase Price |
| Timothy A. Springer, Ph.D.                                 |     |                  123,925.407 |     |     $50,000,000 |
| TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.) |     |                   24,785.081 |     |     $10,000,000 |

In the 2023 Private Placement, Dr. Timothy A. Springer agreed to settle his purchases in three tranches of shares of Series A Preferred Stock, the first for a purchase price of $10.0 million and each thereafter for a purchase price of approximately $20.0 million, with the three tranches settling 30, 60, and 90 days, respectively, following the closing of the transaction. TAS agreed to settle its purchase for approximately $10.0 million within 30 days following the closing of the transaction. The first, second and third tranches were settled on December 13, 2023, January 12, 2024 and February 11, 2024, respectively, under which (i) 24,785.081 shares of Series A Preferred Stock were issued to each of TAS and Dr. Timothy A. Springer in the first tranche, (ii) 49,570.163 shares of Series A Preferred Stock